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Abstract
Although investigators have assessed the relationship between self-reported cigarette smoking and 
biomarker levels, the validity of self-reported information on smokeless tobacco (SLT) use is 
uncertain. We used aggregated data from the 2003–2004, 2005–2006, 2007–2008, and 2009–2010 
administrations of the National Health and Nutrition Examination Survey (NHANES) to compare 
self-reported SLT use with serum concentrations of cotinine, a metabolite of nicotine, among US 
adults aged ≥18 years. Receiver operating characteristic analysis was used to determine the 
optimal serum cotinine cutpoint for discriminating SLT users from nonusers of tobacco, and 
concordance analysis was used to compare self-reported SLT use with cotinine levels. Among the 
30,298 adult respondents who completed the NHANES during 2003–2010, 418 reported having 
exclusively used SLT and no other type of tobacco (cigarettes, cigars, or pipes) during the past 5 
days, while 23,457 reported not using any tobacco. The optimal cotinine cutpoint for 
discriminating SLT users from non–tobacco users was 3.0 ng/mL (sensitivity = 97.0%, specificity 
= 93.0%), which was comparable to a revised cutpoint recommended for identifying adult 
cigarette smokers. Concordance with cotinine was 96.4% and 93.7% for self-reported SLT use and 
tobacco nonuse, respectively. These findings indicate that self-reported SLT use among adults 
correlates highly with serum cotinine levels and that the optimal cutpoint for minimizing 
misclassification of self-reported use is a serum cotinine concentration of 3.0 ng/mL.
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Despite recent declines in cigarette smoking prevalence in the United States, little change 
has occurred in smokeless tobacco (SLT) use (1). In 2011, 3.5% of the US population aged 
≥12 years currently used SLT (1). High levels of carcinogenic tobacco-specific nitrosamines 
have been found in SLT products, especially those formed by fermentation, such as moist 
snuff and chewing tobacco (2).
Surveillance of recent tobacco use is commonly based on population-based self-report 
surveys, which may be subject to misreporting because of inaccurate recall of information 
and can lead to underestimation of tobacco use (3). The degree of undereporting is 
particularly high among groups in which tobacco use is perceived as particularly 
undesirable, including persons with smoking-related diseases and pregnant women (4).
The most frequently utilized biomarker for validation of self-reported smoking data is 
cotinine, a metabolite of nicotine, which can be assessed in serum (5, 6), urine (7, 8), and 
saliva (9, 10). Cotinine has a half-life of 15–20 hours and thus is a useful biomarker for 
assessing recent tobacco use (11). Although investigators have assessed the relationship 
between self-reported smoking and cotinine levels (3), no study has validated self-reported 
SLT use, to our knowledge. Therefore, in this study we used data from the 2003–2010 
administrations of the National Health and Nutrition Examination Survey (NHANES) to 
compare self-reported, past-5-day exclusive SLT use with measured serum cotinine levels 
among US adults aged ≥18 years. Our objectives were to identify the optimal threshold for 
discriminating SLT users from non–tobacco users and to determine the agreement between 
self-reported SLT use and cotinine levels.
METHODS
Data source
NHANES is a household interview and examination survey of the noninstitutionalized US 
population that utilizes a complex, multistage probability sampling design (12). Interviews 
are administered in English or Spanish in respondents’ homes using computer-assisted 
technology. Health examinations and measurements are performed in specially designed and 
equipped mobile examination centers, which travel to various locations throughout the 
country.
We analyzed aggregated data from the 2003–2004, 2005–2006, 2007–2008, and 2009–2010 
waves of the NHANES. Response rates were 79.0%, 80.5%, 78.4%, and 79.4%, 
respectively.
Sample
The study was limited to 2003–2010 NHANES respondents aged ≥18 years for whom data 
on serum cotinine and past-5-day SLT use were available, and who also reported not having 
used a cigarette, cigar, or pipe within the past 5 days. The sample included 23,875 
respondents (418 exclusive SLT users and 23,457 non–tobacco users).
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SLT use—Exclusive SLT users were respondents who reported having used chewing 
tobacco or snuff but no other type of tobacco (cigarettes, cigars, or pipes) during the past 5 
days. Respondents were considered nonusers of any tobacco product if they reported not 
having used SLT, cigarettes, cigars, or pipes during the past 5 days.
Serum cotinine assays—Blood samples were obtained by venipuncture, and serum 
cotinine concentration was assayed using isotope dilution, liquid chromatography, and 
tandem mass spectrometry (13). There were no changes in the NHANES cotinine protocol 
during 2003–2010.
Respondent characteristics—Assessed respondent characteristics included: race/
ethnicity (non-Hispanic white, non-Hispanic black, or Mexican-American); age (18–24, 25–
44, 45–64, or ≥65 years); education (less than 9th grade, 9th–11th grade, high school 
graduation/General Educational Development certificate, or more than high school); poverty 
status (less than poverty level or at or above poverty level); marital status (married or living 
with a partner; widowed, divorced, or separated; or never married); and whether a smoker 
lived in the home (yes or no).
Analysis
Cotinine levels were assessed using descriptive statistics (median values and ranges). Partial 
correlation between the number of days of SLT use during the past 5 days and cotin-ine 
level was also assessed, adjusting for respondent characteristics (α = 0.05).
Receiver operating characteristic curve analysis was used to estimate the optimal threshold 
for discriminating exclusive SLT users from nonusers of any tobacco product (5). Sensitivity 
was defined as the proportion of persons self-reporting exclusive SLT use who had cotinine 
levels at or above the given threshold, while specificity was defined as the proportion of 
persons not reporting tobacco use who had cotinine levels below the given threshold (5). 
The variability of each threshold was assessed using 95% confidence intervals. For 
comparison, we calculated the one-time sensitivity and specificity for all integer values 
within the 95% confidence intervals of the optimal cutpoint, as well as for the fixed cutpoint 
commonly used to discriminate self-reported cigarette smokers from nonsmokers (15 
ng/mL) (14, 15). We assessed the variability of our estimated optimal cutpoint by 
bootstrapping 2,000 times from the data to obtain 95% confidence intervals, with weights 
determined by the survey design. Agreement between self-reports and cotinine levels was 
assessed using concordance analysis, which was performed overall and according to 
respondent characteristics. All analyses were conducted using R, version 2.12.0 (R 
Foundation for Statistical Computing, Vienna, Austria) and Stata, version 11 (Stata-Corp 
LP, College Station, Texas).
RESULTS
Median cotinine concentrations were 293 ng/mL (range, 0.1–1,438) among self-reported 
exclusive SLT users and 0.03 ng/mL (range, 0.01–1,639) among self-reported nonusers of 
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tobacco. Among exclusive SLT users, cotinine levels were correlated with the numbers of 
days on which snuff (ρ = 0.51, P < 0.001) and chewing tobacco (ρ = 0.52, P < 0.001) had 
been used (data not shown).
The optimal cotinine cutpoint that separated self-reported exclusive SLT users from non–
tobacco users was 3.0 ng/mL (95% confidence interval: 1.4, 9.1), with a correct 
classification rate (concordance) of 93.2%, sensitivity of 97.0%, and specificity of 93.0% 
(Table 1). Across cutpoints, concordance ranged from 90.1% (at the 1-ng/mL cutpoint, 
sensitivity = 98% and specificity = 90%) to 94.5% (at the 10-ng/mL cutpoint, sensitivity = 
94% and specificity = 95%). At the cutpoint commonly used for discriminating cigarette 
smokers from nonsmokers (15 ng/mL), the concordance for exclusive SLT users and 
nonusers was 94.8% (sensitivity = 92%, specificity = 95%).
Overall concordance between self-reports and cotinine levels was higher for self-reported 
exclusive SLT users (96.4%) than for non–tobacco users (93.7%) (Table 2). Among self-
reported exclusive SLT users, concordance was higher among females (100%) than among 
males (96.3%). By age, concordance was highest among persons aged ≥65 years (100%) and 
lowest among persons aged 45–64 years (95.4%). By race/ethnicity, concordance ranged 
from 78.5% (Mexican Americans) to 96.7% (non-Hispanic whites). By marital status, 
concordance was highest among persons who were married or living with a partner (96.8%) 
and lowest among persons who had never married (94.0%). By education, concordance was 
highest among those with less than a 9th-grade education (100%) and lowest among those 
with more than a high school education (94.7%). Concordance was lower among persons 
living below the poverty level (88.5%) than among persons living at or above this level 
(97.7%) and higher among persons who lived with a smoker (96.8%) than among those who 
did not (96.3%).
Among self-reported non–tobacco users, concordance was higher among females (95.0%) 
than among males (92.0%) (Table 2). By age, concordance was highest among persons aged 
≥65 years (96.8%) and lowest among persons aged 18–24 years (89.0%). By race/ethnicity, 
concordance ranged from 87.1% (non-Hispanic blacks) to 94.9% (Mexican Ameri-cans). By 
marital status, concordance was highest among those married or living with a partner 
(94.8%) and lowest among those never married (90.5%). By education, concordance was 
highest among those with more than a high school education (95.8%) and lowest among 
those with a 9th- to 11th-grade education (86.7%). Concordance was lower among persons 
living below the poverty level (87.2%) than among persons living at or above this level 
(94.8%), and it was lower among persons who reported living with a smoker (65.0%) than 
among those who did not (96.0%).
DISCUSSION
These study findings reveal that the optimal cotinine cut-point for discriminating between 
exclusive SLT users and non–tobacco users is 3.0 ng/mL. This cutpoint had a high degree of 
sensitivity and specificity among US adults, and it is comparable to a recently revised 
cutpoint for identifying US adult cigarette smokers (3.08 ng/mL) that was revised because of 
declines in population-level secondhand smoke exposure (5). Considerable secondhand 
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smoke exposure can produce serum cotinine levels greater than 10 ng/mL in non-smokers 
(16, 17); thus, a higher cutpoint was required to exclude most nonsmokers (5).
Despite high levels of concordance between past-5-day SLT use and cotinine concentration, 
agreement was lower among self-reported nonusers than among users. This finding may be 
due to changing social norms related to tobacco use and respondents’ reluctance to identify 
themselves as SLT users (5), tobacco smoke exposure among nonusers, or the use of 
emerging tobacco products not assessed by the questionnaire (e.g., snus, dissolvable tobacco 
products, and electronic cigarettes) (18–21).
Disparities in concordance were observed across subpopulations. For instance, concordance 
was lowest among persons aged 18–24 years, which may be a result of young adults being 
more likely to underreport behavior perceived as socially undesirable (9, 22) or the use of 
novel tobacco products among these persons (18–21). This may also be due to higher 
secondhand smoke exposure from peers who smoke; adults aged 18–24 years had one of the 
highest smoking rates of any age group during the study period, ranging from 20.1% in 2010 
to 24.4% in 2005 (23, 24). Disparities were also observed by race/ethnicity. For example, 
concordance between self-reported exclusive SLT use and cotinine level was lowest among 
Mexican Americans. This may be due to the lower prevalence and intensity of tobacco 
consumption among His-panics than among persons of other races/ethnicities and, hence, 
lower cotinine levels that may overlap those of nonusers (5). Differences in nicotine 
metabolism and secondhand smoke exposure may also account for some of the observed 
racial/ethnic differences. Cotinine metabolism is slower among blacks than among persons 
of other races/ethnicities (25, 26), which may explain the relatively low concordance 
between self-reported non–tobacco use and cotinine levels in blacks. Concordance between 
self-reported nonuse and cotinine concentration was also lower among persons living with 
smokers, which may be due to elevated cotinine levels from secondhand smoke exposure 
(17, 27).
With a half-life of 15–20 hours (11), cotinine can only detect recent tobacco use, and thus it 
may not accurately capture occasional use. Additionally, cotinine may not be the ideal bio-
marker for persons who have elevated nicotine levels from secondhand smoke exposure or 
other, nontobacco sources, such as nicotine replacement therapy, or those with occupational 
exposure to pesticides (28, 29). In these situations, an alternative biomarker may be utilized 
for biochemical detection or confirmation of tobacco use. With a half-life of 10–16 days, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanonol (NNAL) may provide a longer window of 
exposure than cotinine in these situations (30, 31).
The observed optimal cutpoint for biochemical confirmation of self-reported exclusive SLT 
use and non–tobacco use (3.0 ng/mL) can have utility in both clinical and research settings. 
Researchers can use this cutpoint for studies of SLT use. Additionally, in settings where 
SLT use is the sole focus of interest, clinicians can use the cutpoint for verification or 
detection of recent use in the absence of other tobacco use. However, this cutpoint would 
predominantly be applicable to white male SLT users, since approximately 91% of the SLT 
users in this study were non-Hispanic white and 97% were male, which is consistent with 
previous studies (32, 33).
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To our knowledge, this study was the first to assess the validity of self-reported SLT use. 
Nonetheless, at least 3 limitations should be noted. First, the sample included only US adults 
and was predominately comprised of non-Hispanic white males; thus, the optimal cotinine 
cutpoint found here may not be generalizable to other countries and subpopulations. Second, 
certain subpopulations had few SLT users, which may have yielded imprecise concordance 
estimates for these groups. Third, the exclusive SLT definition did not account for use of 
nicotine replacement therapy, electronic cigarettes, snus, or dissolvable tobacco products; in 
NHANES, nicotine replacement therapy was assessed only among persons who had tried to 
quit cigarette smoking, while data were unavailable for the then-emerging noncombustible 
tobacco products. However, most of the study period preceded the availability of these 
products in the United States. Additionally, novel SLT products such as snus and dissolvable 
tobacco products account for only a fraction of US SLT use, whereas moist snuff accounted 
for 86.5% of total SLT sales in 2011 (34). As these new SLT products continue to be 
marketed and increase in popularity, it will be important to measure use and to assess 
response validity with future cotinine validation studies.
In conclusion, this study found that among US adults, self-reported SLT use had high 
concordance with cotinine levels, and the optimal cutpoint for discriminating self-reported 
SLT users from non–tobacco users was 3.0 ng/mL. This cutpoint had a high degree of 
sensitivity and specificity and thus may be useful for researchers investigating the 
relationship between SLT use and health, as well as clinicians seeking to verify SLT use.
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Table 1
Sensitivity, Specificity, and Correct Classification Rates for Classification of Smokeless Tobacco Use by 
Cotinine Level Among US Adults Aged ≥18 Years in the National Health and Nutrition Examination Survey, 
2003–2010
Cotinine Cutpoint, ng/mL Sensitivity Specificity % Correctly Classified
1 0.9779 0.8993 90.08
2 0.9681 0.9228 92.36
3a 0.9657 0.9313 93.20
4 0.9559 0.9361 93.65
5 0.9510 0.9385 93.88
6 0.9485 0.9406 94.08
7 0.9485 0.9420 94.21
8 0.9461 0.9435 94.35
9 0.9412 0.9448 94.47
10 0.9363 0.9456 94.54
15b 0.9240 0.9484 94.80
a
Optimal cutpoint (95% confidence interval: 1.4, 9.1).
b
Threshold commonly used in discriminating cigarette smokers from nonsmokers.
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